\babel@toc {english}{}\relax 
\contentsline {paragraph}{Note}{1}{section*.2}%
\contentsline {section}{\numberline {1}Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray}{1}{section.1}%
\contentsline {paragraph}{Keywords}{1}{section*.3}%
\contentsline {paragraph}{Cross-reactive probes}{1}{section*.4}%
\contentsline {paragraph}{Polymorphic CpGs}{2}{section*.5}%
\contentsline {paragraph}{Implications for preprocessing}{2}{section*.6}%
\contentsline {paragraph}{Impact on Illumina 450K analysis}{2}{section*.7}%
\contentsline {section}{\numberline {2}DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer}{2}{section.2}%
\contentsline {paragraph}{Keywords}{2}{section*.8}%
\contentsline {paragraph}{Study design and cohorts}{2}{section*.9}%
\contentsline {paragraph}{Data preprocessing and quality control}{2}{section*.10}%
\contentsline {paragraph}{Adjustment for adipose content (cell-type heterogeneity)}{2}{section*.11}%
\contentsline {paragraph}{Differential variability vs. differential mean}{2}{section*.12}%
\contentsline {paragraph}{iEVORA algorithm and definition of DVMCs}{3}{section*.13}%
\contentsline {paragraph}{Probe reliability and exclusion of technical artifacts}{3}{section*.14}%
\contentsline {paragraph}{Validation in independent cohorts and progression to cancer}{3}{section*.15}%
\contentsline {paragraph}{Pathway-level and regulatory context}{3}{section*.16}%
\contentsline {paragraph}{Clinical correlations}{4}{section*.17}%
\contentsline {paragraph}{Practical takeaway for replication}{4}{section*.18}%
\contentsline {section}{\numberline {3}The integrative epigenomic-transcriptomic landscape of ER-positive breast cancer}{5}{section.3}%
\contentsline {paragraph}{Keywords}{5}{section*.20}%
\contentsline {paragraph}{Study design and rationale}{5}{section*.21}%
\contentsline {paragraph}{Data preprocessing and integration}{5}{section*.22}%
\contentsline {paragraph}{The FEM algorithm}{5}{section*.23}%
\contentsline {paragraph}{Identified FEM modules}{6}{section*.24}%
\contentsline {paragraph}{Validation and reproducibility}{6}{section*.25}%
\contentsline {paragraph}{Integrative clustering (iCluster analysis)}{6}{section*.26}%
\contentsline {paragraph}{Deviation scoring and prognosis}{6}{section*.27}%
\contentsline {paragraph}{Coordination of methylationâ€“expression changes}{6}{section*.28}%
\contentsline {paragraph}{Biological interpretation}{6}{section*.29}%
\contentsline {paragraph}{Summary of methodology for replication}{6}{section*.30}%
\contentsline {paragraph}{Conclusion}{7}{section*.31}%
\contentsline {section}{\numberline {4}Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis}{7}{section.4}%
\contentsline {paragraph}{Keywords}{7}{section*.33}%
\contentsline {paragraph}{Study design and objectives}{7}{section*.34}%
\contentsline {paragraph}{Data preprocessing and feature selection}{7}{section*.35}%
\contentsline {paragraph}{Diagnostic model construction (XGBoost + logistic regression)}{7}{section*.36}%
\contentsline {paragraph}{Functional and genomic annotation of the 7 CpGs}{8}{section*.37}%
\contentsline {paragraph}{Model validation and cross-cancer generalization}{8}{section*.38}%
\contentsline {paragraph}{Prognostic analysis}{8}{section*.39}%
\contentsline {paragraph}{Interpretation and reproducibility}{8}{section*.40}%
\contentsline {paragraph}{Conclusion}{8}{section*.41}%
\contentsline {section}{\numberline {5}DNA Methylation Patterns in Normal Tissue Correlate more Strongly with Breast Cancer Status than Copy-Number Variants}{8}{section.5}%
\contentsline {paragraph}{Keywords}{8}{section*.43}%
\contentsline {paragraph}{Study objectives}{9}{section*.44}%
\contentsline {paragraph}{Datasets and preprocessing}{9}{section*.45}%
\contentsline {paragraph}{Cell-type deconvolution and reference construction}{9}{section*.46}%
\contentsline {paragraph}{Identification of differentially variable CpGs (DVMCs)}{9}{section*.47}%
\contentsline {paragraph}{CNV calling and comparative analysis}{9}{section*.48}%
\contentsline {paragraph}{Risk prediction and model validation}{10}{section*.49}%
\contentsline {paragraph}{Interpretation and implications}{10}{section*.50}%
\contentsline {paragraph}{Conclusion}{10}{section*.51}%
\contentsline {section}{\numberline {6}Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer}{10}{section.6}%
\contentsline {paragraph}{Keywords}{10}{section*.52}%
\contentsline {paragraph}{Study design and datasets}{10}{section*.53}%
\contentsline {paragraph}{Methylation and expression profiling}{10}{section*.54}%
\contentsline {paragraph}{Statistical framework}{11}{section*.55}%
\contentsline {paragraph}{DFNA5 methylation landscape}{11}{section*.56}%
\contentsline {paragraph}{Relationship between methylation and expression}{11}{section*.57}%
\contentsline {paragraph}{Diagnostic classifier}{11}{section*.58}%
\contentsline {paragraph}{Clinicopathological correlations}{11}{section*.59}%
\contentsline {paragraph}{Prognostic relevance}{11}{section*.60}%
\contentsline {paragraph}{Replication protocol}{12}{section*.61}%
\contentsline {paragraph}{Conclusion}{12}{section*.62}%
